About Summit:
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.
Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:
Non-small Cell Lung Cancer (NSCLC)
HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.
HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.
Colorectal Cancer (CRC)
HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.
Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.
Overview of Role:
The Head, National Field Medical (Head) is a senior leader responsible for shaping and executing the US field medical strategy in oncology across multiple tumor types. Reporting to the SVP, Global Medical Affairs, the Head will oversee two-tier field teams of Medical Science Directors (RMSDs), each leading field engagement within defined US regions, managed by regional leads. This individual will build scalable capabilities to enable launch excellence, drive scientific and operational effectiveness, and ensure support for pipeline developments in multiple oncological indications. Highly action oriented, the Head will partner cross-functionally with Medical Affairs, Commercial, Clinical Development, Clinical Operations, Market Access, and other teams to ensure effective, fair, balanced, and compliant interactions with HCPs, KOLs, and decision makers advancing disease and product knowledge and understanding.
Role and Responsibilities:
Strategic Leadership
Develop and lead the US field medical strategy for oncology, ensuring alignment with global medical, clinical, and commercialization objectives.
Oversee the planning and execution of field medical activities supporting the first NSCLC launch, future launches, and lifecycle management across multiple tumor types.
Design and integrate platforms and dashboards that improve team effectiveness.
Team Management
Cultivate an inclusive, high-performing, action-oriented culture grounded in scientific rigor and integrity.
Lead several Regional leaders and their territory RMSDs to ensure strong regional coverage and execution of field medical initiatives.
Own the field talent strategy, including hiring, onboarding, competency assessment, coaching, career paths, succession planning, and retention.
Scientific Engagement & Insight Generation
Guide RMSDs in building and maintaining relationships with KOLs, HCPs, and other external stakeholders, in line with national and regional engagement strategies developed with therapeutic area leads, to support…